Alamar Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Alamar Biosciences

10/08/2026 22:38

Alamar Biosciences Inc ALMR.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended June 30.  The mean expectation of five analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -40 cents to -25 cents per share.
Revenue was $29.43 million​; analysts expected $25.94 million. 
Alamar Biosciences Inc's reported EPS for the quarter was a loss of 22 cents​.
The company reported a quarterly loss of $13.2 million.
Alamar Biosciences Inc shares had risen by 5.1% this quarter.
FORECAST CHANGES
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Alamar Biosciences Inc is $32.00, about 11.1% above its last closing price of $28.46
This summary was machine generated from LSEG data August 10 at 09:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.33
-0.22
Beat